BioCryst Pharmaceuticals
BCRX
230 hedge funds and large institutions have $2.07B invested in BioCryst Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 93 increasing their positions, 61 reducing their positions, and 36 closing their positions.
136% more call options, than puts
Call options by funds: $53M | Put options by funds: $22.5M
52% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 61
11% more capital invested
Capital invested by funds: $1.87B → $2.07B (+$200M)
4.24% more ownership
Funds ownership: 79.93% → 84.17% (+4.2%)
6% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 36
2% less funds holding
Funds holding: 234 → 230 (-4)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$25.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$24.8M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$24.7M |
| 4 |
State Street
Boston,
Massachusetts
|
+$21.5M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$17.6M |
Top Sellers
| 1 |
Millennium Management
New York
|
-$16.3M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$15.4M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$12.3M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$11.4M |
| 5 |
Fisher Asset Management
Camas,
Washington
|
-$9.14M |
BCRX Hedge Fund Activity: Q4 2022 in Review
230 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q4 2022, worth a combined $2.07B — up 11% from $1.87B a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of BCRX and 34 opened new positions — a net loss of 2 holders — while 61 trimmed existing stakes and 93 added.
The largest buyer was Woodline Partners, opening a new position worth an estimated $25.8M. The largest seller was Millennium Management, cutting an estimated $16.3M.
- 230 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q4 2022, down from 234 in Q3 2022.
- Funds reported $2.07B of BioCryst Pharmaceuticals stock for Q4 2022, up 11% quarter-over-quarter.
- 34 funds opened new BioCryst Pharmaceuticals positions in Q4 2022 and 36 closed out, a net change of -2 holders.
- The largest BioCryst Pharmaceuticals buyer in Q4 2022 was Woodline Partners, an estimated $25.8M added.
- The largest BioCryst Pharmaceuticals seller in Q4 2022 was Millennium Management, an estimated $16.3M sold.
Based on aggregated 13F filings for Q4 2022.